Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Foghorn Therapeutics (Nasdaq: FHTX) announced management will participate in two investor conferences: TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 11:10 a.m. EDT and The Citizens Life Sciences Conference on March 11, 2026 at 11:20 a.m. EDT.

Adrian Gottschalk, President and CEO, will present at both events and take one-on-one meetings. A webcast of the TD Cowen presentation will be available in the company investors section for 90 days.

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Foghorn^® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the TD Cowen 46^th Annual Health Care Conference and The Citizens Life Sciences Conference. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

TD Cowen 46th Annual Health Care Conference

• Presentation: Tuesday, March 3, 2026, at 11:10 a.m. EDT
• Presenter: Adrian Gottschalk, President and Chief Executive Officer
• Registration Link: Register here
• Management will also participate in one-on-one meetings
  
  

The Citizens Life Sciences Conference

• Presentation: Wednesday, March 11, 2026, at 11:20 a.m. EDT
• Presenter: Adrian Gottschalk, President and Chief Executive Officer
• Management will also participate in one-on-one meetings
  
  

A webcast of the TD Cowen presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com, and will be available for 90 days.

About Foghorn Therapeutics
Foghorn^® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control^® platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X and LinkedIn.

Contact:
Karin Hellsvik, Foghorn Therapeutics Inc.
khellsvik@foghorntx.com

FAQ

When will Foghorn Therapeutics (FHTX) present at the TD Cowen 46th Annual Health Care Conference?

Foghorn will present on March 3, 2026 at 11:10 a.m. EDT. According to the company, Adrian Gottschalk, President and CEO, will deliver the presentation and participate in one-on-one investor meetings the same day.

How can investors watch Foghorn Therapeutics' (FHTX) TD Cowen presentation if they cannot attend?

A webcast of the TD Cowen presentation will be available via the company investors site for 90 days. According to the company, the replay is posted under “Events & Presentations” on the investor relations website.

When and who will present for Foghorn Therapeutics (FHTX) at The Citizens Life Sciences Conference?

Foghorn will present on March 11, 2026 at 11:20 a.m. EDT, with Adrian Gottschalk, President and CEO, as presenter. According to the company, management will also hold one-on-one investor meetings surrounding the event.

Where can investors register to attend Foghorn Therapeutics (FHTX) conference presentations and meetings?

Investors can register through the conference registration links provided by the conference organizers. According to the company, registration information and webcast access are available via the investor relations section of the company website.

What does Foghorn Therapeutics (FHTX) highlight about its research focus in these presentations?

Foghorn emphasizes an initial focus in oncology and its Gene Traffic Control platform. According to the company, the platform and pipeline aim to correct abnormal gene expression across a broad spectrum of diseases.